Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 14

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 14
---
 to the Exchange Act of 1934, as amended (the “Exchange Act”), including annual and quarterly
reports, and other reports we file, are available for inspection and review on the website of the SEC at www.sec.gov. In addition, we
also make available, free of charge, through our website at www.mosaicie.com, our reports filed with the SEC or by written request to
the Company at Mosaic ImmunoEngineering, Inc., 9114 Adams Avenue, #202, Huntington Beach, California 92646, Attention: Corporate Secretary.
The information contained in, or that can be accessed through, our website is not part of, and is not incorporated in this Report, and
should not be relied upon.

Smaller
Reporting Company

We are currently a “smaller reporting company”
as defined by Rule 12b-2 of the Exchange Act, and are thus allowed to provide simplified executive compensation disclosures in our filings,
are exempt from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring that an independent registered public accounting
firm provide an attestation report on the effectiveness of internal control over financial reporting and have certain other reduced disclosure
obligations with respect to our SEC filings.

 8 

    ITEM 1A.
    RISK FACTORS

Investing in our common stock is speculative and
illiquid and involves a high degree of risk including the risk of a loss of your entire investment. You should carefully consider the
risks and uncertainties described below and the other information contained in this Annual Report on Form 10-K (“Report”)
before investing in our common stock. The risks set forth below are not the only ones facing us. Additional risks and uncertainties may
exist that could also adversely affect our business, operations and prospects. If any of the following risks actually materialize, our
business, financial condition, prospects and/or operations could suffer. In such event, the value of our common stock could decline, and
you could lose all or a substantial portion of the money that you pay for our common stock.

Unless the context otherwise requires, references
to the “Company,” the “combined company,” “Mosaic,” “we,” “our,” or “us”
in this Report refer to Mosaic ImmunoEngineering, Inc. and its subsidiaries (formerly known as Patriot Scientific Corporation). References
to “PTSC” refer to Patriot Scientific Corporation prior to the completion of the Reverse Merger and references to “Private
Mosaic